The possible anti-atherogenic effect of adiponectin is currently under discussion, and its low level is seen as an indicator of IR, a high risk of developing metabolic syndrome and cardiovascular disease (Li et al., 2009). The gene discussed is ADIPOQ; the disease is metabolic syndrome.